visilizumab

Phase 2Monoclonal antibody

FFacet Biotech

visilizumab is one of 149 small molecule programs targeting Anal fistula. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anal FistulaActive, not recruiting

LymphomaActive, not recruiting

Acute Graft Versus Host DiseaseActive, not recruiting

Ulcerative ColitisActive, not recruiting

Graft Versus Host DiseaseActive, not recruiting

Anal FistulaPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Acute Graft Versus Host DiseasePhase 1/Phase 2

Active, not recruiting

Ulcerative ColitisPhase 2/Phase 3

Active, not recruiting

Graft Versus Host DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

visilizumab

FFacet Biotech

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis7 trials

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Terminated·FFacet Biotech·Phase 2/3·NCT00279422·127 enrolled

Research Study in Patients With Severe Ulcerative Colitis

Completed·FFacet Biotech·Phase 2/3·NCT00032305·20 enrolled

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Completed·FFacet Biotech·Phase 1/2·NCT00267306·144 enrolled

Show 4 more trials

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Terminated·AAbbott·Phase 2·NCT00307827·38 enrolled

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Terminated·PPDL BioPharma, Inc.··NCT00355901·300 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Withdrawn·FFacet Biotech·Phase 3·NCT00502294·150 enrolled

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Terminated·FFacet Biotech·Phase 2/3·NCT00279435·25 enrolled

Acute Graft Versus Host Disease1 trial

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Completed·FFacet Biotech·Phase 1/2·NCT00032292·34 enrolled

Lymphoma1 trial

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

Completed·SStanford University·Phase 1·NCT00006009

Graft Versus Host Disease1 trial

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Unknown status·FFred Hutchinson Cancer Center·Phase 2·NCT00032279·80 enrolled

Anal fistula1 trial

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Completed·FFacet Biotech·Phase 2·NCT00267709·18 enrolled

3 more indications

PD-1 Inhibitor1 trial

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04722952·30 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00720629·8 enrolled

Crohn's Disease1 trial

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Completed·FFacet Biotech·Phase 2·NCT00267722·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for visilizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — visilizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for visilizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Facet Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: FFacet Biotech

visilizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis7 trials

Acute Graft Versus Host Disease1 trial

Lymphoma1 trial

Graft Versus Host Disease1 trial

Anal fistula1 trial

PD-1 Inhibitor1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News